Eisai invests in Altoida

Japanese pharma group Eisai is investing in the Lucerne startup Altoida. The companies have also entered into a research partnership. Altoida is building a digital engine to power early Alzheimer’s disease identification.

Altoida is developing a digital solution for early detection of Alzheimer's disease. Generic image: geralt/Pixabay

The Lucerne startup Altoida has secured funding from Eisai Innovation, as was reported in a press release. It is a strategic investment subsidiary of Japanese pharma group Eisai. The investment amount has not been disclosed.  

Altoida and Eisai will continue to collaborate on research in future as well. This will help drive forward the solution for the early identification of Alzheimer’s disease. The development is based on augmented reality and artificial intelligence. Users complete a set of digital and augmented reality activities on their smartphone or tablet. This collects a range of diagnostic digital biomarkers for Alzheimer’s disease, which are analyzed using artificial intelligence. Doctors then use these results to predict the potential risk.

“The work Altoida is doing with digital biomarkers may prove to revolutionize how we approach dementias, including Alzheimer’s disease,” said Kazumasa Nagayama, Chief Strategy Officer at Eisai. This innovation helps identify patients in need of therapy earlier and enables interventions “years ahead of traditional methods”.

Handbook for Investors

Our Handbook for Investors provides valuable information about technologies and production costs, taxes and financing, as well as the legal system and infrastructure in Switzerland. Browse through the complete handbook online or download the chapters most relevant to you.

How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program